Iowa Senate Bill SF433

Iowa 2025-2026 Regular Session

• Introduced: 2/25/25
• Refer: 2/25/25

Caption

A bill for an act relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission.

Impact

The bill mandates a review by the Iowa medical assistance drug utilization review commission regarding the inclusion of the medication vosevi into the preferred drug list. This review is to be completed by July 1, 2026. The incorporation of vosevi as a preferred antiviral would facilitate broader access to effective treatment options for individuals affected by hepatitis C within the state, signaling a proactive approach to public health management and disease control.

Summary

Senate File 433, introduced by Senator Wahls, addresses the regulations surrounding direct acting antiviral medications specifically focused on their use in treating hepatitis C. One significant provision of the bill is the elimination of prior authorization requirements for these medications that are included on the preferred drug list for the Iowa medical assistance program. This change aims to improve access to necessary treatments for patients suffering from hepatitis C, allowing them to receive medication without facing bureaucratic delays.

Contention

While the bill has clear public health benefits, discussions around the proposal may highlight concerns regarding the cost implications for the state Medicaid program. Critics could argue that bypassing prior authorization might increase overall drug expenditure, straining the fiscal resources allocated to health services. Those in favor believe the long-term health benefits outweigh immediate budgetary concerns, as improved access to treatment can lead to enhanced public health outcomes and potential cost savings down the line from decreased healthcare resources needed for untreated hepatitis C.